



November 30, 2012

Gene Techno Science Co., Ltd.  
Code :4584 (TSE Mothers)  
President  
Masanari Kawaminami

## **Approval for Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF) in Japan**

Recombinant human granulocyte colony-stimulating factor (rhG-CSF, our development code: GBS-001) has been approved for Japanese marketing authorization on November 21, 2012. This biological product was co-developed as a filgrastim biosimilar with Fuji Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd.

rhG-CSF stimulates the differentiation and proliferation of neutrophilic precursor cells into neutrophils, mobilizes the peripheral blood progenitor cells (PBPC), and activates the function of mature neutrophils. Therefore, rhG-CSF is indicated for neutropenia in patients with cytotoxic chemotherapy for malignancy, for the reduction in the duration of neutropenia in patients by bone marrow transplantation, (and for the treatment of persistent neutropenia in patients with advanced HIV infection, in order to reduce the risk of bacterial infections).

This rhG-CSF is the first rhG-CSF biosimilar approved in Japan, and will be marketed under two brand names and through two sales channels in Japan by Fuji Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd.

Approval of rhG-CSF will accelerate alliances with pharmaceutical company in EU, US and emerging countries to collaborate on the global development of rhG-CSF.

This approval will not impact the financial results of our company for the fiscal year ending March 2013.

### **Media Contact**

Shin-ichi Kamachi  
Business Development Dept.  
Tel: (81)-3-3517-1353  
E-mail : info@g-gts.com